Elena Porcú

Dr. Elena Porcú

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
MCMartina Castellan
Martina Castellan
AGAlberto Guarnieri
Alberto Guarnieri
AFAtsushi Fujimura
Atsushi Fujimura
FZFrancesca Zanconato
Francesca Zanconato
GBGiusy Battilana
Giusy Battilana
SPStefano Piccolo
Stefano Piccolo

4 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FRFrancesco Roncato
Francesco Roncato
FRFatlum Rruga
Fatlum Rruga
EPElena Porcú
Elena Porcú
ECElisabetta Casarin
Elisabetta Casarin
RRRoberto Ronca
Roberto Ronca
Margherita MorpurgoMargherita Morpurgo
Margherita Morpurgo
Nowadays, personalized cancer therapy relies on small molecules, monoclonal antibodies, or antibody–drug conjugates (ADC). Many nanoparticle (NP)-based drug delivery systems are also actively investigated, but their advantage over ADCs has not been demonstrated yet. Here, using the Avidin-Nucleic-Acid-Nano-Assemblies (ANANAS), a class of polyavidins multifuctionalizable with stoichiometric control, we compare quantitatively anti-EGFR antibody(cetuximab)-targeted NPs to the corresponding ADC. We show that ANANAS tethering of cetuximab promotes a more efficient EGFR-dependent vesicle-mediated internalization. Cetuximab-guided ANANAS carrying doxorubicin are more cytotoxic in vitro and much more potent in vivo than the corresponding ADC, leading to 43% tumor reduction at low drug dosage (0.56 mg/kg). Advantage of cetuximab-guided ANANAS with respect to the ADC goes beyond the increase in drug-to-antibody ratio. Even if further studies are needed, we propose that NP tethering could expand application of the anti-EGFR antibody to a wider number of cancer patients including the KRAS-mutated ones, currently suffering from poor prognosis.

19 May 2021 in Blood
Verified
Journal Article
Closed access
PDF file
GBGiulia Borella
Giulia Borella
ARAmbra Da Ros
Ambra Da Ros
EPElena Porcú
Elena Porcú
CTClaudia Tregnago
Claudia Tregnago
MBMaddalena Benetton
Maddalena Benetton
MARTINA PIGAZZIMARTINA PIGAZZI
MARTINA PIGAZZI
Bone marrow (BM) microenvironment contributes to the regulation of normal hematopoiesis through a finely tuned balance of self-renewal and differentiation processes, cell-cell interaction and secretion of cytokines that during leukemogenesis are altered and favor tumor cell growth. In pediatric acute myeloid leukemia (AML), chemotherapy is the standard of care, but still >30% of patients relapse. The need to accelerate the evaluation of innovative medicines prompted us to investigate the mesenchymal stromal cells (MSCs) role in the leukemic niche to define its contribution to the mechanisms of leukemia escape. We generated humanized three-dimensional (3D) niche with AML cells and MSCs derived from either patients (AML-MSCs) or healthy donors. We observed that AML cells establish physical connections with MSCs, mediating a reprogrammed transcriptome inducing aberrant cell proliferation and differentiation, and severely compromising their immunomodulatory capability. We confirmed that AML cells modulate h-MSCs transcriptional profile promoting functions similar to the AML-MSCs when co-cultured in vitro, thus facilitating leukemia progression. Conversely, MSCs derived from BM of patients at time of disease remission showed recovered healthy features, at transcriptional and functional levels, including the secretome. We proved that AML blasts alter MSCs activities in the BM niche, favoring disease development and progression. We discovered that a novel AML-MSCs selective CaV1.2 channel blocker drug, Lercanidipine, is able to impair leukemia progression in 3D niche both in vitro and when implanted in vivo, if used in combination with chemotherapy, supporting the hypothesis that synergistic effects can be obtained by dual targeting approaches.

21 December 2017 in Blood
Verified
Journal Article
Closed access
PDF file
Valentina SerafinValentina Serafin
Valentina Serafin
GCGiorgia Capuzzo
Giorgia Capuzzo
GMGloria Milani
Gloria Milani
SMSonia Anna Minuzzo
Sonia Anna Minuzzo
MPMarica Pinazza
Marica Pinazza
BABenedetta Accordi
Benedetta Accordi
Pediatric T-acute lymphoblastic leukemia (T-ALL) patients often display resistance to glucocorticoid (GC) treatment. These patients, classified as prednisone poor responders (PPR), have poorer outcome than do the other pediatric T-ALL patients receiving a high-risk adapted therapy. Because glucocorticoids are administered to ALL patients during all the different phases of therapy, GC resistance represents an important challenge to improving the outcome for these patients. Mechanisms underlying resistance are not yet fully unraveled; thus our research focused on the identification of deregulated signaling pathways to point out new targeted approaches. We first identified, by reverse-phase protein arrays, the lymphocyte cell-specific protein-tyrosine kinase (LCK) as aberrantly activated in PPR patients. We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations. This was confirmed by specific LCK gene silencing and ex vivo combined treatment of cells from PPR patient-derived xenografts. Moreover, we observed that LCK hyperactivation in PPR patients upregulates the calcineurin/nuclear factor of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression. GC-sensitive cells cultured with IL-4 display an increased resistance to dexamethasone, whereas the inhibition of IL-4 signaling could increase GC-induced apoptosis in resistant cells. Treatment with dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo. Our results suggest a quickly actionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-ALL patients. Key Points Resistance to glucocorticoid treatment in pediatric T-ALL can be reversed by LCK inhibitors in vitro and in vivo. IL-4 overexpression contributes to LCK-induced glucocorticoid resistance. Visual Abstract

1 September 2014 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
EPElena Porcú
Elena Porcú
RBRoberta Bortolozzi
Roberta Bortolozzi
GBGiuseppe Basso
Giuseppe Basso
Giampietro ViolaGiampietro Viola
Giampietro Viola
Vascular disrupting agents (VDAs) are an important class of compounds that exhibit selective activity against pre-existing tumor vasculature, causing rapid shutdown of the tumor blood flow and consequent necrosis of the tumor mass. The VDAs can be divided into flavonoid compounds, which are related to flavone acetic acid, and tubulin-binding agents. Tubulin-binding agents represent the largest group of VDAs and are characterized by different chemical structures, although most of them are derivatives of the lead compound combretastatin (CA-4). They demonstrated clinical activity, although recent findings have established that they have insufficient activity as single agents. Several resistance mechanisms occur, such as the resistance of the tumor rim cells, while promising results have been described in combination with other chemotherapeutics.

15 July 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RRRomeo Romagnoli
Romeo Romagnoli
PBPier Giovanni BARALDI
Pier Giovanni BARALDI
MSMaria Kimatrai Salvador
Maria Kimatrai Salvador
FPFilippo Prencipe
Filippo Prencipe
VBValerio Bertolasi
Valerio Bertolasi
Giampietro ViolaGiampietro Viola
Giampietro Viola